Subcutaneous Emphysema in COVID-19 Managed with Surgical Tracheostomy: A Case Series
Abstract
Background: The coronavirus disease 2019 (COVID-19) is a multi-system infection which predominantly affects the respiratory system. Subcutaneous emphysema with or without pneumomediastinum and pneumothorax been recently reported as an unusual complication in cases of severe COVID-19 pneumonia. Case presentation: We report three cases of COVID-19 pneumonia complicated by subcutaneous emphysema with all cases showed resolution of emphysema with chest tube followed by tracheostomy. Conclusion: Due to growing number of cases that developed coronavirus infection associated with subcutaneous emphysema, this approach can be considered in treating such condition. However, the timing and efficacy of tracheostomy in COVID-19 patient with subcutaneous emphysema still remain elusive and more studies are needed to confirm the role of tracheostomy in managing subcutaneous emphysema.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.